Bristol Myers Squibb have announced a $400 million investment in their Dublin 15 Cruiserath Campus towards the build and design of a Sterile Drug Product facility.
Niall Balfour, Chief Executive Officer at Tower Cold Chain, explores the sustainability implications associated with both single-use, semi-reusable and fully reusable temperature-controlled shippers.
Takeda and Biological E. Limited, an India-based vaccines and pharmaceutical company, have announced a strategic partnership to accelerate access to QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials.
In our latest EPM Online Insight, Andy Clarke, Country Manager (UK), at YSDS explores the complexities and demands of low volume, high value shipments through specialist logistics support.
Bryan Hill (Global / Americas), Gaga Syal (GGM) & Rohit Alimchandani (UK) - Cognizant discuss how life sciences organisations should prepare for the quantum revolution in our latest EPM Online Insights.
FUJIFILM Healthcare Europe has unveiled the ECHELON Synergy, a revolutionary MRI scanner for efficient, high performance imaging with optimal patient comfort.
Jimin Kim, Senior CDO Business Strategist at Samsung Biologics, lays out the challenges of successfully progressing complex biologics from clinic to commercialisation.
In our latest EPM Online Insight, ACG's Subhashis Chakraborty and Shincy Jacob attempt to answer what groundbreaking innovations lie ahead for capsules, and how will these developments redefine their role in the evolving landscape of drug delivery?
EPM Editor Jai McIntosh recently caught up with Campbell Bunce, Chief Scientific Officer and Cambridge Site Head at Abzena to discuss Abzena’s ThioBridge technology.
Niklas Adamsson, COO at Envirotainer explores the key trends set to shape the pharmaceutical cold chain in 2024 – a sector that carries an immense responsibility with lives depending on its success.
Nicholas Panico, Scientific and Regulatory Affairs Specialist at Symbio Proinnovera explores Eczema and Our Evolving Environment in our latest EPM Online Insight.
Zuellig Pharma has announced that it has completed the acquisition of two brands, Cialis (Tadalafil) and Alimta (Pemetrexed), from Eli Lilly and Company for select ASEAN markets.
